BIBA Medical Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News Neuro News CX Symposium ilegx BIBA Med PA BIBA Research
Members login
  Password reminder

RegisterEdit your account | View you account

Interventional News

The international website for interventionalists 

 

Experts gather at Olbert Workshop

Erich Minar and Johannes Lammer
Erich Minar and Johannes Lammer

A highlight of the German speaking interventional radiolgy calendar is the Friedrich Olbert interventional workshop, which took place this year between the 11th and 14th of January in Munich. Friedrich Olbert, for those who do not already know of him and his reputation, works in the surgery department of the Wien Lainz. He has established a reputation as one of Europe's leading interventional radiologists and was president and founder of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in 1985.

This meeting has been going under its present name since 1994, although it grew from a smaller meeting started in 1981. This year's congress president was Johannes Lammer from Vienna, supported by a scientific committee that included significant members of the German speaking interventional radiology community such as Dierk Vorwerk from Ingolstadt and Hermann Berger from the Klinikum rechts der Isar Muenchen.

As usual the exhibition was a mixture of live cases and lectures on clinical practice and new technologies. We focused on the sessions on Friday and Saturday but, according to conversations we had had with attendees, there had been plenty of interest on earlier days including a session on cutting balloons and CryoPlasty, and a series of interesting live cases.

Thomas Rand
Thomas Rand
Jim Reekers
Jim Reekers
The first session we attended was the honorary lecture on the inferior vena cava (IVC) filter that looked at current developments with this product. The lecture was presented by Rolf Guenther of Aachen. He examined the different devices on the market including permanent and temporary devices. He said he believed that there is a bright future for retrievable filters, and presented many data to support this. He contended that trial data support the use of retrievable filters for up to a year and predicted that in the future this could commonly stretch to 1.5 years. He also believed that repositioning IVC filters was both a viable and advisable technique.

In the late afternoon, Ulrich Hoffmann of Munich gave a presentation on critical ischaemia and the definition and standards of non-invasive diagnosis. He was followed by HJ Wagner on percutaneous transluminal angioplasty (PTA) techniques. He said he believed that coronary balloons and guidewires were completely unavailable for this area. He also supported the use of coronary balloons for long lesions.

Thomas Rand of Vienna then spoke about the range of stents that could be used in infrapopliteal arteries. He showed data that supported the use of passive coated stents like the Carbostent from Sorin. He became enthusiastic when he showed the results, which demonstrated successful use of drug-eluting stents (DES): 96% technical success and 90% clinical success. He felt that DES could become the dominant stent for this pathology, with the sirolominus-eluting stent being a slightly better option in this area, and looked forward to longer-term clinical trials.
Rolf Guenther
Rolf Guenther
Rand also looked at bioabsorable stents and in particular the BioSTAR Evaluation STudy (BEST), of which Marc Bosiers is the principal investigator. Once again he commented that the trial results pointed to a bright future and concluded that although PTA would continue to be used, especially for small stenoses, the opinion on the use of stents in this area was moving rapidly from "could be of major importance" to "would be of major importance". On questioning he said he believed the use of stents could reduce the need for amputation in patients with infrapopoliteal artery disease by 10%.

Saturday
Saturday began with Lammer going through the latest TASC recommendations. Most significant was the extension of the recommendation of endovascular treatment in most cases for type B lesions and not just type A lesions. As before the recommendation was for type C lesions was both surgical or endovascular depending on the on the lesion. With type D the preferred indication is surgical with endovascular in certain special cases (See page 1).

Jim Reekers looked at the EVAR and DREAM trials. While we have already covered this discussion extensively in the past, he did make the important point that clinicians should base their decisions on an informed analysis of trial results rather than any preconception they had of endovascular or surgical treatment. He also stated that young patients with low co-morbidity and long life expectancy might be better treated with open surgery and was waiting with interest for detailed ten-year follow-up on the effectiveness of stent grafts.

Erich Minar of Vienna looked at the Arteria femoralis superficialis (AFS) trials. He felt that there were not enough data to support widespread use of cyroplasty or cutting balloons.

The last talk on Saturday looked at uterine artery embolisation (UAE) and, after examining study results, concluded that after a technically successful UAE there should be only a 5% hysterectomy rate, typical with re-intervention. While he supported this for up to two years he felt that the future for embolisation was good.

All in all, this was a very useful meeting as it covered a wide spectrum of new techniques and technologies and also presented a balanced view of the latest clinical trends in interventional radiology.


Latest News



Monday, 21 May 2012


Features





Profiles





BIBA Medical, 44 Burlington Road, Fulham, London, SW6 4NX.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions